NPS PHARMACEUTICALS INC 4

Accession 0000890465-13-000035

CIK 0000890465operating

View on SEC.gov Company Profile

Filed

Dec 18, 7:00 PM ET

Accepted

Dec 19, 5:51 PM ET

Size

31.3 KB

Accession

0000890465-13-000035

Insider Transaction Report

Form 4

Period: 2013-12-17

NPS PHARMACEUTICALS INCNPSP

STRATEMEIER ED

SVP & Acting GC

Transactions

Exercise/Conversion
Stock Options
2013-12-17−50,972→ 34,473 total
Exercise: $3.60Exp: 2019-10-19→ Common Stock (50,972 underlying)
Exercise/Conversion
Stock Options
2013-12-18−14,062→ 8,438 total
Exercise: $8.25Exp: 2021-02-17→ Common Stock (14,062 underlying)
Exercise/Conversion
Common Stock
2013-12-18$3.60/sh+34,473$124,103→ 76,812 total
Exercise/Conversion
Common Stock
2013-12-18$6.16/sh+43,750$269,500→ 171,187 total
Sale
Common Stock
2013-12-18$25.17/sh−154,460$3,887,758→ 42,339 total
Exercise/Conversion
Stock Options
2013-12-18−34,473→ 0 total
Exercise: $3.60Exp: 2019-10-19→ Common Stock (34,473 underlying)
Exercise/Conversion
Stock Options
2013-12-18−11,550→ 14,850 total
Exercise: $8.21Exp: 2022-02-07→ Common Stock (11,550 underlying)
Exercise/Conversion
Common Stock
2013-12-18$3.34/sh+50,625$169,088→ 127,437 total
Exercise/Conversion
Common Stock
2013-12-18$8.21/sh+11,550$94,826→ 196,799 total
Exercise/Conversion
Stock Options
2013-12-18−50,625→ 39,375 total
Exercise: $3.34Exp: 2020-02-19→ Common Stock (50,625 underlying)
Exercise/Conversion
Common Stock
2013-12-18$8.25/sh+14,062$116,012→ 185,249 total
Exercise/Conversion
Stock Options
2013-12-18−43,750→ 6,250 total
Exercise: $6.16Exp: 2020-05-07→ Common Stock (43,750 underlying)
Exercise/Conversion
Common Stock
2013-12-17$3.60/sh+50,972$183,499→ 93,311 total
Sale
Common Stock
2013-12-17$25.00/sh−50,972$1,274,300→ 42,339 total

Footnotes (8)

[F1]The exercises and sales made by the Reporting Person and disclosed in this Form 4 are in anticipation of his retirement, which was disclosed in a Form 8-K filed by the Issuer with the Securities and Exchange Commission today, December 19, 2013.
[F2]The shares were sold pursuant to a predefined price target in a trading plan qualified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, that was effective December 13, 2013.
[F3]The price shown above represents the weighted average price of the shares sold. The range of sales prices was $25.00 and $25.46. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid.
[F4]On October 19, 2009, the Reporting Person received a grant of 100,000 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter. As of the date of this filing, 100,000 stock options have vested.
[F5]On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. As of December 18, 2013, the performance criteria for 50,625 of these options has been satisfied. The options become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.
[F6]On May 7, 2010, the Reporting Person received a grant of 50,000 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter. As of the date of this filing, 43,750 stock options have vested.
[F7]On February 17, 2011, the Reporting Person received a grant of 22,500 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter. As of the date of this filing, 15,468 stock options have vested.
[F8]On February 7, 2012, the Reporting Person received a grant of 26,400 stock options under the Issuer's 2005 Stock Option Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter. As of the date of this filing, 11,550 stock options have vested.

Documents

1 file

4
edgar.xmlPrimary
PRIMARY DOCUMENT

Issuer

NPS PHARMACEUTICALS INC

CIK 0000890465

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0000890465

Filing Metadata

Form type: 4
Filed: Dec 18, 7:00 PM ET
Accepted: Dec 19, 5:51 PM ET
Size: 31.3 KB

View on SEC.gov